{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:49:05Z","timestamp":1792723745885,"version":"4.5.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.anai.2022.10.004","type":"journal-article","created":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T07:16:54Z","timestamp":1665559014000},"page":"15-20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Current state of biologics in treating eosinophilic esophagitis"],"prefix":"10.1016","volume":"130","author":[{"given":"Quan M.","family":"Nhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema S.","family":"Aceves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.anai.2022.10.004_bib0001","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.gie.2013.10.027","article-title":"A phenotypic analysis shows that eosinophilic esophagitis is a progressive fibrostenotic disease","volume":"79","author":"Dellon","year":"2014","journal-title":"Gastrointest Endosc"},{"issue":"17","key":"10.1016\/j.anai.2022.10.004_bib0002","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1056\/NEJMra1502863","article-title":"Eosinophilic esophagitis","volume":"373","author":"Furuta","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.anai.2022.10.004_bib0003","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1053\/j.gastro.2017.06.067","article-title":"Epidemiology and natural history of eosinophilic esophagitis","volume":"154","author":"Dellon","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.anai.2022.10.004_bib0004","article-title":"Type 2 inflammation in eosinophilic esophagitis: from pathophysiology to therapeutic targets","volume":"12","author":"Racca","year":"2021","journal-title":"Front Physiol"},{"issue":"6","key":"10.1016\/j.anai.2022.10.004_bib0005","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/s41395-018-0052-5","article-title":"The natural course of eosinophilic esophagitis and long-term consequences of undiagnosed disease in a large cohort","volume":"113","author":"Warners","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.anai.2022.10.004_bib0006","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3389\/fmed.2017.00128","article-title":"Tissue remodeling in chronic eosinophilic esophageal inflammation: parallels in asthma and therapeutic perspectives","volume":"4","author":"Nhu","year":"2017","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"10.1016\/j.anai.2022.10.004_bib0007","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/MCG.0000000000000297","article-title":"Impact of diagnostic delay and other risk factors on eosinophilic esophagitis phenotype and esophageal diameter","volume":"50","author":"Lipka","year":"2016","journal-title":"J Clin Gastroenterol"},{"issue":"4","key":"10.1016\/j.anai.2022.10.004_bib0008","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.gie.2014.02.012","article-title":"The natural history of steroid-naive eosinophilic esophagitis in adults treated with endoscopic dilation and proton pump inhibitor therapy over a mean duration of nearly 14 years","volume":"80","author":"Lipka","year":"2014","journal-title":"Gastrointest Endosc"},{"issue":"3","key":"10.1016\/j.anai.2022.10.004_bib0009","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.anai.2018.05.035","article-title":"Summary of the updated international consensus diagnostic criteria for eosinophilic esophagitis: AGREE conference","volume":"121","author":"Spergel","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"10.1016\/j.anai.2022.10.004_bib0010","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1053\/j.gastro.2018.07.009","article-title":"Updated international consensus diagnostic criteria for eosinophilic esophagitis: proceedings of the AGREE Conference","volume":"155","author":"Dellon","year":"2018","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.anai.2022.10.004_bib0011","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11938-019-00216-7","article-title":"New developments in the diagnosis and treatment of eosinophilic esophagitis","volume":"17","author":"Nhu","year":"2019","journal-title":"Curr Treat Options Gastroenterol"},{"issue":"62","key":"10.1016\/j.anai.2022.10.004_bib0012","doi-asserted-by":"crossref","first-page":"eabi5586","DOI":"10.1126\/sciimmunol.abi5586","article-title":"Clonally expanded, GPR15-expressing pathogenic effector TH2 cells are associated with eosinophilic esophagitis","volume":"6","author":"Morgan","year":"2021","journal-title":"Sci Immunol"},{"issue":"4","key":"10.1016\/j.anai.2022.10.004_bib0013","first-page":"207","article-title":"Update on emerging pharmacologic therapies for patients with eosinophilic esophagitis","volume":"18","author":"Syverson","year":"2022","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"2","key":"10.1016\/j.anai.2022.10.004_bib0014","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1053\/j.gastro.2017.05.066","article-title":"Diagnosis and treatment of eosinophilic esophagitis","volume":"154","author":"Straumann","year":"2018","journal-title":"Gastroenterol"},{"issue":"13","key":"10.1016\/j.anai.2022.10.004_bib0015","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/jama.2021.14920","article-title":"Eosinophilic esophagitis: a review","volume":"326","author":"Muir","year":"2021","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.anai.2022.10.004_bib0016","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.anai.2018.05.006","article-title":"Medical and dietary management of eosinophilic esophagitis","volume":"121","author":"Nhu","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"10.1016\/j.anai.2022.10.004_bib0017","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s12016-018-8674-3","article-title":"Biological therapies for eosinophilic esophagitis: where do we stand?","volume":"55","author":"Ko","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"issue":"2","key":"10.1016\/j.anai.2022.10.004_bib0018","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.gtc.2014.02.015","article-title":"Clinical implications and pathogenesis of esophageal remodeling in eosinophilic esophagitis","volume":"43","author":"Hirano","year":"2014","journal-title":"Gastroenterol Clin North Am"},{"issue":"6","key":"10.1016\/j.anai.2022.10.004_bib0019","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.cgh.2018.09.005","article-title":"Clinical and molecular factors associated with histologic response to topical steroid treatment in patients with eosinophilic esophagitis","volume":"17","author":"Eluri","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.anai.2022.10.004_bib0020","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1053\/j.gastro.2019.09.052","article-title":"Approaches and challenges to management of pediatric and adult patients with eosinophilic esophagitis","volume":"158","author":"Hirano","year":"2020","journal-title":"Gastroenterol"},{"issue":"10","key":"10.1016\/j.anai.2022.10.004_bib0021","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1038\/ctg.2017.47","article-title":"Improvement in esophageal distensibility in response to medical and diet therapy in eosinophilic esophagitis","volume":"8","author":"Carlson","year":"2017","journal-title":"Clin Transl Gastroenterol"},{"issue":"7","key":"10.1016\/j.anai.2022.10.004_bib0022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/dote\/dox042","article-title":"Control of inflammation decreases the need for subsequent esophageal dilation in patients with eosinophilic esophagitis","volume":"30","author":"Runge","year":"2017","journal-title":"Dis Esophagus"},{"issue":"12","key":"10.1016\/j.anai.2022.10.004_bib0023","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1038\/ctg.2015.62","article-title":"Early comparison of inflammatory vs. fibrostenotic phenotype in eosinophilic esophagitis in a multicenter longitudinal study","volume":"6","author":"Singla","year":"2015","journal-title":"Clin Transl Gastroenterol"},{"issue":"1","key":"10.1016\/j.anai.2022.10.004_bib0024","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jaci.2015.05.045","article-title":"Long-term assessment of esophageal remodeling in patients with pediatric eosinophilic esophagitis treated with topical corticosteroids","volume":"137","author":"Rajan","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2022.10.004_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaci.2019.11.011","article-title":"Diagnosis and treatment of eosinophilic esophagitis","volume":"145","author":"Gonsalves","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2022.10.004_bib0026","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/ueg2.12216","article-title":"Close follow-up is associated with fewer stricture formation and results in earlier detection of histological relapse in the long-term management of eosinophilic esophagitis","volume":"10","author":"Bon","year":"2022","journal-title":"United European Gastroenterol J"},{"issue":"8","key":"10.1016\/j.anai.2022.10.004_bib0027","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.cgh.2021.10.028","article-title":"A gap in care leads to progression of fibrosis in eosinophilic esophagitis patients","volume":"20","author":"Chang","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.anai.2022.10.004_bib0028","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/ajg.2017.267","article-title":"Editorial: deep remission in eosinophilic esophagitis with long-term steroids: difficult to attain and maintain","volume":"112","author":"Alexander","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"10.1016\/j.anai.2022.10.004_bib0029","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1038\/ajg.2017.202","article-title":"Long-term treatment of eosinophilic esophagitis with swallowed topical corticosteroids: development and evaluation of a therapeutic concept","volume":"112","author":"Greuter","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.anai.2022.10.004_bib0030","doi-asserted-by":"crossref","first-page":"139","DOI":"10.18176\/jiaci.0254","article-title":"Dupilumab: a new paradigm for the treatment of allergic diseases","volume":"28","author":"Sastre","year":"2018","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"8","key":"10.1016\/j.anai.2022.10.004_bib0031","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1097\/01.MIB.0000172557.39767.53","article-title":"Cytokine expression in healthy and inflamed mucosa: probing the role of eosinophils in the digestive tract","volume":"11","author":"Straumann","year":"2005","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"10.1016\/j.anai.2022.10.004_bib0032","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.jaci.2007.10.024","article-title":"IL-13 involvement in eosinophilic esophagitis: transcriptome analysis and reversibility with glucocorticoids","volume":"120","author":"Blanchard","year":"2007","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2022.10.004_bib0033","first-page":"294","article-title":"Novel therapeutic approaches to eosinophilic esophagitis","volume":"16","author":"Beveridge","year":"2020","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"10.1016\/j.anai.2022.10.004_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2022.102183","article-title":"Eosinophilic esophagitis: new molecules, better life?","volume":"63","author":"Lam","year":"2022","journal-title":"Curr Opin Pharmacol"},{"issue":"2","key":"10.1016\/j.anai.2022.10.004_bib0035","doi-asserted-by":"crossref","first-page":"426","DOI":"10.3390\/cells10020426","article-title":"Heterogeneity of intestinal tissue eosinophils: potential considerations for next-generation eosinophil-targeting strategies","volume":"10","author":"Masterson","year":"2021","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.anai.2022.10.004_bib0036","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.jaci.2006.09.007","article-title":"Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis","volume":"118","author":"Stein","year":"2006","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2022.10.004_bib0037","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bjd.17869","article-title":"Conjunctivitis in dupilumab clinical trials","volume":"181","author":"Akinlade","year":"2019","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.anai.2022.10.004_bib0038","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/gut.2009.178558","article-title":"Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial","volume":"59","author":"Straumann","year":"2010","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.anai.2022.10.004_bib0039","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2011.07.044","article-title":"An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis","volume":"141","author":"Assa'ad","year":"2011","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.anai.2022.10.004_bib0040","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.jaci.2013.02.042","article-title":"Anti-IL-5 therapy reduces mast cell and IL-9 cell numbers in pediatric patients with eosinophilic esophagitis","volume":"131","author":"Otani","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2022.10.004_bib0041","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1097\/MPG.0000000000001840","article-title":"Safety and efficacy of reslizumab for children and adolescents with eosinophilic esophagitis treated for nine years","volume":"66","author":"Markowitz","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"2","key":"10.1016\/j.anai.2022.10.004_bib0042","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jaci.2011.11.044","article-title":"Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial","volume":"129","author":"Spergel","year":"2012","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"10.1016\/j.anai.2022.10.004_bib0043","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s11882-020-00928-2","article-title":"Eosinophilic esophagitis: existing and upcoming therapies in an age of emerging molecular and personalized medicine","volume":"20","author":"Slack","year":"2020","journal-title":"Curr Allergy Asthma Rep"},{"issue":"7","key":"10.1016\/j.anai.2022.10.004_bib0044","first-page":"e16460","article-title":"Plausible role of asthma biological modifiers in the treatment of eosinophilic esophagitis","volume":"13","author":"Olsen","year":"2021","journal-title":"Cureus"},{"issue":"14","key":"10.1016\/j.anai.2022.10.004_bib0045","doi-asserted-by":"crossref","first-page":"4502","DOI":"10.12998\/wjcc.v10.i14.4502","article-title":"Histological remission of eosinophilic esophagitis under asthma therapy with IL-5 receptor monoclonal antibody: a case report","volume":"10","author":"Huguenot","year":"2022","journal-title":"World J Clin Cases"},{"issue":"6","key":"10.1016\/j.anai.2022.10.004_bib0046","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jaip.2022.02.037","article-title":"Benralizumab completely depletes gastrointestinal tissue eosinophils and improves symptoms in eosinophilic gastrointestinal disease","volume":"10","author":"Kuang","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"20","key":"10.1016\/j.anai.2022.10.004_bib0047","doi-asserted-by":"crossref","first-page":"e96789","DOI":"10.1172\/jci.insight.96789","article-title":"Synaptopodin is upregulated by IL-13 in eosinophilic esophagitis and regulates esophageal epithelial cell motility and barrier integrity","volume":"2","author":"Rochman","year":"2017","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.anai.2022.10.004_bib0048","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jaci.2014.07.049","article-title":"Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis","volume":"135","author":"Rothenberg","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2022.10.004_bib0049","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jaci.2020.03.045","article-title":"An anti-IL-13 antibody reverses epithelial-mesenchymal transition biomarkers in eosinophilic esophagitis: phase 2 trial results","volume":"146","author":"Gann","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"10.1016\/j.anai.2022.10.004_bib0050","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.cgh.2013.03.020","article-title":"Esophageal distensibility as a measure of disease severity in patients with eosinophilic esophagitis","volume":"11","author":"Nicod\u00e8me","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.anai.2022.10.004_bib0051","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1055\/s-0042-107340","article-title":"Severity of endoscopically identified esophageal rings correlates with reduced esophageal distensibility in eosinophilic esophagitis","volume":"48","author":"Chen","year":"2016","journal-title":"Endoscopy"},{"issue":"5","key":"10.1016\/j.anai.2022.10.004_bib0052","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.anai.2022.01.019","article-title":"Improvement in eosinophilic esophagitis when using dupilumab for other indications or compassionate use","volume":"128","author":"Spergel","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"10.1016\/j.anai.2022.10.004_bib0053","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0113483","article-title":"A pilot study of omalizumab in eosinophilic esophagitis","volume":"10","author":"Loizou","year":"2015","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.anai.2022.10.004_bib0054","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s00431-011-1540-4","article-title":"Omalizumab in the treatment of eosinophilic esophagitis and food allergy","volume":"170","author":"Rocha","year":"2011","journal-title":"Eur J Pediatr"},{"issue":"12","key":"10.1016\/j.anai.2022.10.004_bib0055","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1172\/JCI6560","article-title":"Fundamental signals that regulate eosinophil homing to the gastrointestinal tract","volume":"103","author":"Mishra","year":"1999","journal-title":"J Clin Invest"},{"issue":"7","key":"10.1016\/j.anai.2022.10.004_bib0056","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.14309\/ajg.0000000000001213","article-title":"Eosinophilic esophagitis onset despite six years\u2019 treatment with omalizumab in an asthmatic patient: no protective effect for anti-IgE therapy?","volume":"116","author":"Franceschini","year":"2021","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.anai.2022.10.004_bib0057","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0150968","article-title":"Preferential secretion of thymic stromal lymphopoietin (TSLP) by terminally differentiated esophageal epithelial cells: relevance to eosinophilic esophagitis (EoE)","volume":"11","author":"Chandramouleeswaran","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.anai.2022.10.004_bib0058","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jaci.2020.10.018","article-title":"Replication and meta-analyses nominate numerous eosinophilic esophagitis risk genes","volume":"147","author":"Kottyan","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2022.10.004_bib0059","doi-asserted-by":"crossref","first-page":"G13","DOI":"10.1152\/ajpgi.00290.2015","article-title":"Elevated IL-33 expression is associated with pediatric eosinophilic esophagitis, and exogenous IL-33 promotes eosinophilic esophagitis development in mice","volume":"310","author":"Judd","year":"2016","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"5","key":"10.1016\/j.anai.2022.10.004_bib0060","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.jaci.2016.02.034","article-title":"Allergic skin sensitization promotes eosinophilic esophagitis through the IL-33-basophil axis in mice","volume":"138","author":"Venturelli","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"10.1016\/j.anai.2022.10.004_bib0061","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1007\/s10620-019-05704-5","article-title":"Resolution of refractory eosinophilic esophagitis with the leukocyte-trafficking inhibitor natalizumab","volume":"64","author":"Beales","year":"2019","journal-title":"Dig Dis Sci"},{"issue":"11","key":"10.1016\/j.anai.2022.10.004_bib0062","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/j.cgh.2018.06.022","article-title":"The potential role of vedolizumab in concomitant eosinophilic esophagitis and Crohn's disease","volume":"16","author":"Taft","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.anai.2022.10.004_bib0063","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/s41395-018-0145-1","article-title":"The anti-\u03b14\u03b27 integrin therapeutic antibody for inflammatory bowel disease, vedolizumab, ameliorates eosinophilic esophagitis: a novel clinical observation","volume":"113","author":"Nhu","year":"2018","journal-title":"Am J Gastroenterol"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120622018300?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120622018300?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:29:33Z","timestamp":1761053373000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120622018300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S1081120622018300"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2022.10.004","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current state of biologics in treating eosinophilic esophagitis","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2022.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}